Woodline Partners’s Cidara Therapeutics CDTX Stock Holding History

Woodline Partners’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-67,500	Closed	-$14.9M	–	1046
2025 Q4	$14.9M	Buy	67,500 +27,460	+69%	+$4.44M	0.06%	370
2025 Q3	$3.83M	Sell	40,040 -21,000	-34%	-$1.34M	0.02%	617
2025 Q2	$2.97M	Buy	+61,040	New	+$1.47M	0.02%	658

Woodline Partners's CDTX Position: Q1 2026 in Review

Woodline Partners sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 67,500 shares — an estimated $14.9M sold.

Woodline Partners first reported a position in CDTX in Q2 2025 and held it in 3 quarters. The position peaked at $14.9M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Woodline Partners reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Woodline Partners sold 67,500 Cidara Therapeutics shares in Q1 2026, an estimated $14.9M.
Woodline Partners first reported a position in Cidara Therapeutics in Q2 2025 and held it in 3 quarters.
Woodline Partners's Cidara Therapeutics position peaked at $14.9M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.